glycine has been researched along with Lymphopenia in 1 studies
Lymphopenia: Reduction in the number of lymphocytes.
Excerpt | Relevance | Reference |
---|---|---|
"Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18." | 2.77 | Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. ( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ma, WW | 1 |
Messersmith, WA | 1 |
Dy, GK | 1 |
Weekes, CD | 1 |
Whitworth, A | 1 |
Ren, C | 1 |
Maniar, M | 1 |
Wilhelm, F | 1 |
Eckhardt, SG | 1 |
Adjei, AA | 1 |
Jimeno, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors[NCT01125891] | Phase 1 | 39 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for glycine and Lymphopenia
Article | Year |
---|---|
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ce | 2012 |